Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | Chief Financial Officer | March 20, 2026 | March 24, 2026 |
| FibroBiologics, Inc.FBLG · Entity 7875 | Director | June 23, 2026 | June 24, 2026 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | CFO & SVP, Finance | December 19, 2019 | December 23, 2019 |
| INNOVUS PHARMACEUTICALS, INC.INNV · Entity 151567 | CHIEF FINANCIAL OFFICER | September 06, 2016 | November 21, 2016 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director | June 22, 2021 | June 23, 2021 |
| MABVAX THERAPEUTICS HOLDINGS, INC.MBVX · Entity 167746 | Director | May 19, 2017 | May 23, 2017 |
| TuHURA Biosciences, Inc./NVHURA · Entity 6601 | Director | February 12, 2026 | February 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date March 20, 2026 · Filed March 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2036-03-20 | Direct | 4,874,691 |
Reported balance
After 2026-03-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-20 · Grant · Acquired 4,874,691 · Balance 4,874,691 F1: This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan"). F2: 1,218,672 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan").
F2: 1,218,672 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030.
FibroBiologics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2036-06-22 | Direct | 30,803 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 30,803 · Balance 30,803 F1: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.
HERON THERAPEUTICS, INC. /DE/
Report date December 19, 2019 · Filed December 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.02 · Expires 2029-12-19 | Direct | 100,000 |
Reported balance
After 2019-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-12-19 · Grant · Acquired 100,000 · Balance 100,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant.
INNOVUS PHARMACEUTICALS, INC.
Report date September 06, 2016 · Filed November 21, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock unitsSEC Table II · derivative / convertible security · Expires 2026-11-16 | Direct | 2,500,000 |
Reported balance
After 2016-09-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-09-06 · Grant · Acquired 2,500,000 · Balance 2,500,000 F1: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2: The Reporting Person was granted a Restricted Stock Unit on September 6, 2016 of 2,500,000 shares, which shall vest according to the following schedule: 1/3 after one year of employment with the Issuer and then in equal quarterly increments over the next eight quarters upon continuous employment with the Company. F3: These restricted stock units were granted pursuant to the Issuer's 2016 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
F2: The Reporting Person was granted a Restricted Stock Unit on September 6, 2016 of 2,500,000 shares, which shall vest according to the following schedule: 1/3 after one year of employment with the Issuer and then in equal quarterly increments over the next eight quarters upon continuous employment with the Company.
F3: These restricted stock units were granted pursuant to the Issuer's 2016 Equity Incentive Plan.
Kura Oncology, Inc.
Report date June 22, 2021 · Filed June 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $21.54 · Expires 2031-06-21 | Direct | 23,000 |
Reported balance
After 2021-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-22 · Grant · Acquired 23,000 · Balance 23,000 F1: This option vests in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full on the one year anniversary of the date of grant.
MABVAX THERAPEUTICS HOLDINGS, INC.
Report date May 19, 2017 · Filed May 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2027-05-19 | Direct | 50,000 |
Reported balance
After 2017-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-19 · Grant · Acquired 50,000 · Balance 50,000 F1: The option is fully vested and exercisable and was issued pursuant to conditions of the Letter Agreement, dated May 15, 2017, by and between the Company and the lead investor in connection with the Company's public offering completed on May 19, 2017, and filed with the Securities and Exchange Commission on May 22, 2017 as Exhibit A of Exhibit 10.2 of the Company's Quarterly Report on Form 10-Q. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and exercisable and was issued pursuant to conditions of the Letter Agreement, dated May 15, 2017, by and between the Company and the lead investor in connection with the Company's public offering completed on May 19, 2017, and filed with the Securities and Exchange Commission on May 22, 2017 as Exhibit A of Exhibit 10.2 of the Company's Quarterly Report on Form 10-Q.
TuHURA Biosciences, Inc./NV
Report date February 12, 2026 · Filed February 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2036-02-12 | Direct | 156,240 |
Reported balance
After 2026-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 156,240 · Balance 156,240 F1: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2035-01-02 | Direct | 51,275 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 51,275 F2: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.
F2: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aravive, Inc.
Report date April 08, 2020 · Filed April 09, 2020
Section 16 reporting ended · disclosed 2020-04-09. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
CombiMatrix Corp
Report date November 14, 2017 · Filed November 16, 2017
Section 16 reporting ended · disclosed 2017-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-11-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-11-14 · Disposition to issuer · Disposed 2,001 · Balance 6,618 F1: Represents common stock of the issuer underlying restricted stock units that were cancelled in the merger pursuant to merger agreement between issuer and Invitae Corporation in exchange for 1,737 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. Row 2 · 2017-11-14 · Other · Disposed 6,618 · Balance 0 F2: Disposed of pursuant to merger agreement between issuer and Invitae Corporation in exchange for 5,752 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.80 · Expires 2018-12-20 | Direct | 0 |
Reported balance
After 2017-11-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-14 · Other · Acquired 1,619 · Balance 0 F3: This warrant was assumed by Invitae in the merger and replaced with a warrant to purchase 1,407 shares of Invitae common stock for $53.84 per share. F2: Disposed of pursuant to merger agreement between issuer and Invitae Corporation in exchange for 5,752 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common stock of the issuer underlying restricted stock units that were cancelled in the merger pursuant to merger agreement between issuer and Invitae Corporation in exchange for 1,737 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger.
F2: Disposed of pursuant to merger agreement between issuer and Invitae Corporation in exchange for 5,752 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger.
F3: This warrant was assumed by Invitae in the merger and replaced with a warrant to purchase 1,407 shares of Invitae common stock for $53.84 per share.
Esperion Therapeutics, Inc.
Report date July 13, 2026 · Filed July 13, 2026
Section 16 reporting ended · disclosed 2026-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 1
1 source rowRow 1 · 2026-07-13 · Disposition to issuer · Disposed 85,153 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2035-04-01 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-13 · Disposition to issuer · Disposed 40,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-13 · Disposition to issuer · Disposed 7,040 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions.
F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2017 Filed Jun 12, 2017 21:48 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 10,000 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001209191-17-039256 · doc4.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common stock · 10,000 shares Expires 2027-06-08 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| May 19, 2017 Filed May 23, 2017 20:09 UTC | MABVAX THERAPEUTICS HOLDINGS, INC. MBVX · Entity 167746 | GrantOption to Purchase Common Stock · Derivative | 50,000 | $1.80 Strike: $1.80 | $90,000.00 |
DisclosureSEC source: 0001415889-17-000843 · form4-05232017_050543.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-05-19 F1 · derivative.exercise_date: The option is fully vested and exercisable and was issued pursuant to conditions of the Letter Agreement, dated May 15, 2017, by and between the Company and the lead investor in connection with the Company's public offering completed on May 19, 2017, and filed with the Securities and Exchange Commission on May 22, 2017 as Exhibit A of Exhibit 10.2 of the Company's Quarterly Report on Form 10-Q. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 00:54 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $15.30 | $0.00 |
DisclosureSEC source: 0001209191-17-028037 · doc4.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2027-04-24 F1 · derivative.exercise_date: Options shall vest and become exercisable with respect to 32,500 shares on the first anniversary of his first day of employment (the "Grant Date"), followed by 97,500 shares vesting ratably each month over the subsequent three years, such that 130,000 options will be fully vested on the four year anniversary of the Grant Date. Read SEC document |
| April 02, 2017 Filed Apr 4, 2017 19:23 UTC | MABVAX THERAPEUTICS HOLDINGS, INC. MBVX · Entity 167746 | Exercise / conversionRestricted Stock Unit · Derivative | 1,543 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-17-000594 · form4-04042017_040405.xml · derivative · entry 2 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,543 Underlying: Common Stock · 1,543 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer F2 · price: Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer F3 · derivative.exercise_date: Restricted Stock Units vest over 3 years from April 2, 2015, 1/3 on each anniversary of the date of grant, subject to the Reporting Person's continued employment or service with the Issuer on each such vesting date. F3 · derivative.expiration_date: Restricted Stock Units vest over 3 years from April 2, 2015, 1/3 on each anniversary of the date of grant, subject to the Reporting Person's continued employment or service with the Issuer on each such vesting date. Read SEC document |
| April 02, 2017 Filed Apr 4, 2017 19:23 UTC | MABVAX THERAPEUTICS HOLDINGS, INC. MBVX · Entity 167746 | Exercise / conversionCommon Stock | 1,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-17-000594 · form4-04042017_040405.xml · nonDerivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents conversion of restricted stock units into common stock upon vesting of 1/3 of such units granted on April 2, 2015. F1 · price: Represents conversion of restricted stock units into common stock upon vesting of 1/3 of such units granted on April 2, 2015. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 20:57 UTC | MABVAX THERAPEUTICS HOLDINGS, INC. MBVX · Entity 167746 | GrantOption to Purchase Common Stock · Derivative | 4,100 | $3.38 Strike: $3.38 | $13,858.00 |
DisclosureSEC source: 0001415889-17-000022 · form4-01032017_050126.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2027-01-01 F1 · derivative.exercise_date: Such Options shall vest in equal annual installments over a three year period. Read SEC document |
| September 06, 2016 Filed Nov 21, 2016 11:00 UTC | INNOVUS PHARMACEUTICALS, INC. INNV · Entity 151567 | GrantRestricted Stock units · Derivative | 2,500,000 | $0.27 | $675,000.00 |
DisclosureSEC source: 0001415889-16-007484 · form4-11212016_061118.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Common Stock · 2,500,000 shares Expires 2026-11-16 F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_price: The Reporting Person was granted a Restricted Stock Unit on September 6, 2016 of 2,500,000 shares, which shall vest according to the following schedule: 1/3 after one year of employment with the Issuer and then in equal quarterly increments over the next eight quarters upon continuous employment with the Company. F3 · kind: These restricted stock units were granted pursuant to the Issuer's 2016 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.